The NHS is made up of more than 8,000 organisations, with many more across the wider health and care sector.
The NHS has launched the world’s largest trial of a revolutionary new blood test that can detect more than 50 types of cancer before symptoms appear.
The Galleri(tm) test checks for the earliest signs of cancer in the blood and the NHS-Galleri trial, the first of its kind, aims to recruit 140,000 volunteers in eight areas of England to see how well the test works in the NHS. The first people to take part will have blood samples taken at mobile testing clinics in retail parks and other convenient community locations.
The test is a simple blood test that research has shown is particularly effective at finding cancers that are typically difficult to identify early – such as head and neck, bowel, lung, pancreatic, and throat cancers. It works by finding chemical changes in fragments of genetic code-cell-free DNA (cfDNA) that leak from tumours into the bloodstream. The NHS is already sending out letters inviting tens of thousands of people from different backgrounds and ethnicities aged between 50 and 77 to take part.
Participants, who must not have had a cancer diagnosis in the last three years, will be asked to give a blood sample at a locally based mobile clinic and they will then be invited back after 12 months, and again at two years, to give further samples. The trial is part of the NHS’s efforts to increase the proportion of cancers detected early by the end of the Long Term Plan.
Amanda Pritchard, NHS England chief executive, said: “This quick and simple blood test could mark the beginning of a revolution in cancer detection and treatment here and around the world. By finding cancer before signs and symptoms even appear, we have the best chance of treating it and we can give people the best possible chance of survival.
“The NHS has a successful track record of leading the way on innovations in cancer diagnosis and treatment, from CAR-T therapy to Covid-friendly drugs. The Galleri blood test, if successful, could play a major part in achieving our NHS Long Term Plan ambition to catch three quarters of cancers at an early stage, when they are easier to treat. So if you are invited, please take part – you could be helping us to revolutionise cancer care and protect yourself.”
Dame Cally Palmer, NHS National Director for Cancer, said: “It is an absolute priority to speed up the earlier detection of cancer to improve survival, and this trial has the potential to do just that across a range of types of cancer. We are very grateful to all the people who will be taking part in this important initiative, which could help us save many more lives in the future.”
The NHS-Galleri trial is being run by The Cancer Research UK and King’s College London Cancer Prevention Trials Unit in partnership with the NHS and healthcare company, GRAIL, which has developed the Galleri test. It is operating with the support of eight NHS Cancer Alliances across England that span Cheshire and Merseyside, Cumbria, Greater Manchester, the North East, West Midlands, East Midlands, East of England, Kent and Medway, and South East London. For the purposes of the trial, only people living in these areas will be invited.
Initial results of the study are expected by 2023 and, if successful, the NHS in England plans to extend the rollout to a further one million people in 2024 and 2025.
Health and Social Care Secretary Sajid Javid said: “The UK’s world leading scientists continue to pioneer innovative cancer diagnosis and treatments so our brilliant NHS staff have the tools to spot the disease as early as possible and give people the care they need.
“Early diagnosis can save lives and this revolutionary new test can detect cancers before symptoms even appear, giving people the best possible chance of beating the disease. Ensuring fewer people need treatment for advanced cancer is vital for patient care and another example of the NHS innovating to be more efficient – which will be crucial in bringing down the backlog.”
By lowering the risk of surgical site infections, Ethicon’s Plus Sutures may be able to help the National Health Service at a time of unprecedented pressure.